Login
$HIMS
$18.55 -$0.01 (0.07%) After hours

$HIMS 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

On November 4, 2026, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) increased the size of the Board from nine to ten directors and appointed Dr. Andrew Huberman, 51, to fill the newly created directorshi...

09 Nov 2026 8-K: Results of Operations and Financial Condition; Other Events

Revenue of approximately $890 million, up 49% year-over-year in Q3 2026

07 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 5, 2026, Jonathan M. Franklin commenced employment with Hims & Hers Health, Inc. (the “Company”) as chief accounting officer. On October 7, 2026, the Company's board of directors appointed Mr. Franklin as principal accounting ...

10 Aug 2026 8-K: Results of Operations and Financial Condition

Revenue of approximately $753 million, up 38% year-over-year in Q2 2026

17 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On July 13, 2026, Irene Becklund informed Hims & Hers Health, Inc. (the “Company”) of her intention to resign as Chief Accounting Officer and Principal Accounting Officer, effective as of October 9, 2026. Ms. Becklund has indicated to th...

01 Jul 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

This MASTER RECEIVABLES PURCHASE AGREEMENT (as it may be amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) is made as of July 1, 2026, among XeCare LLC, a Delaware limited liability company, as a ...

15 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

(a)(b) On June 11, 2026, Hims & Hers Health, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in m...

02 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

THIS AMENDMENT NO. 3 (this “Amendment”), dated as of May 29, 2026, by and among HIMS & HERS HEALTH, INC., a Delaware corporation (the “Borrower”), and each existing Lender party hereto, which constitute at least the Required Lenders unde...

21 May 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

INDENTURE, dated as of May 21, 2026, between Hims & Hers Health, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).

19 May 2026 8-K: Other Events

Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

11 May 2026 8-K: Results of Operations and Financial Condition

Revenue of approximately $608 million, up 4% year-over-year in Q1 2026

11 Mar 2026 8-K: Regulation FD Disclosure

Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s

23 Feb 2026 8-K: Results of Operations and Financial Condition

Revenue of approximately $2.35 billion, up 59% year-over-year in 2025

19 Feb 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

CERTAIN INFORMATION CONTAINED IN THIS SECURITIES SALE DEED HAS, PURSUANT TO ITEM 601(B)(2) OF REGULATION S-K, BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE SUCH INFORMATION IS BOTH NOT MATER...

17 Nov 2025 8-K: Other Events

On November 13, 2025, the Board of Directors of Hims & Hers Health, Inc. (the “Company”) authorized and approved a new share repurchase program (the “2025 Share Repurchase Program”) pursuant to which the Company may repurchase up to $250...

03 Nov 2025 8-K: Results of Operations and Financial Condition

Revenue of nearly $600 million, up 49% year-over-year in Q3 2025

02 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

On September 28, 2025, Nader Kabbani, the Chief Operating Officer of Hims & Hers Health, Inc. (the “Company”) determined to step into a new advisory role for the Company effective November 2, 2025 (the “Transition Date”), where he will c...

22 Sep 2025 8-K: Other Events

Investors of Hims & Hers Health, Inc. (the "Company") and others should note that we announce information to the public about the Company, the products and services available on the Company’s platform, and other updates regarding the Com...

05 Sep 2025 8-K: Entry into a Material Definitive Agreement

The submission of an unsigned copy of this document to Tenant for Tenant’s consideration does not constitute an offer to lease the Premises or an option to or for the Premises. This document shall become effective and binding only upon t...

04 Aug 2025 8-K: Results of Operations and Financial Condition; Other Events

Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support